In advanced NSCLC, positive PD-L1 expression, evaluated by TPS, usually distributes as one-third in the PD-L1 <1% group, one-third in the PD-L1 1% to 49% group, and one-third in the PD-L1 ≥50% group [25]. Here, CD274 is linked to non-small cell lung carcinoma.